Search clinical trials for: KHK4827 (brodalumab)

Total 61 results

Kyowa Kirin Korea Co., Ltd.

Completed

A Study of KHK4827 (Brodalumab) in Subjects With Moderate to Severe Psoriasis in Korea

Moderate to Severe Plaque Psoriasis

Korea, Republic of
Kyowa Kirin Co., Ltd.

Completed

A Study of KHK4827 in Subjects With Palmoplantar Pustulosis

Palmoplantar Pustulosis

Japan
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin China Pharmaceutical Co., LTD.

Withdrawn

A Phase 4 Study of Brodalumab (KHK4827) in Subjects With Moderate to Severe Plaque Psoriasis

Moderate to Severe Plaque Psoriasis

China
Kyowa Kirin Co., Ltd.

Completed

An Open-label, Non-controlled Study of KHK4827 in Subjects With Psoriasis

Psoriasis

Japan
Kyowa Kirin Co., Ltd.

Completed

A Phase 2 Clinical Study of KHK4827

Moderate to Severe Plaque Psoriasis

Japan
Kyowa Kirin Co., Ltd.

Completed

A Phase 3 Clinical Study of KHK 4827

Psoriasis Vulgaris | Psoriatic Arthritis | Pustular; Psoriasis, Palmaris Et Plantaris | Psoriatic Erythroderma

Japan
Kyowa Kirin Co., Ltd.

Active, not recruiting

A Phase 3 Study of KHK4827 in Patients With Systemic Sclerosis

Moderate to Severe Systemic Sclerosis

Japan
Kyowa Kirin Co., Ltd.

Active, not recruiting

A Study of KHK4827 in Patients With Systemic Sclerosis

Systemic Sclerosis

Japan
Kyowa Kirin Co., Ltd.

Completed

A Study of KHK4827 in Subjects With Axial Spondyloarthritis (axSpA)

Axial Spondyloarthritis

Korea, Republic of, Taiwan, Japan
Kyowa Kirin Co., Ltd.

Completed

A Clinical Pharmacology of KHK4827 in Healthy Volunteers and Subject With Moderate to Severe Psoriasis

Psoriasis

Japan
Kyowa Kirin Co., Ltd.

Completed

A Phase 3 Clinical Study of KHK4827

Psoriasis

Japan
Bausch Health Americas, Inc.

Terminated

Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects (AMAGINE-1)

Psoriasis

United States, Germany, Poland, Switzerland, France, Canada
Bausch Health Americas, Inc.

Completed

Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis (AMVISION-2)

Psoriatic Arthritis

United States, France, Hungary, Mexico, Poland, Germany, Canada, Greece, Russian Federation, Latvia
Icahn School of Medicine at Mount Sinai

Completed

Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies

Psoriasis

United States
Amgen

Withdrawn

Study of Efficacy and Safety of Brodalumab Compared With Placebo in Subjects With Axial Spondyloarthritis

Axial Spondyloarthritis

United States, Canada
MedDerm Associates

Terminated

Study to Evaluate Broadlumab vs Placebo and Ustekinumab (AMAGINE-3)

Psoriasis

United States
Bausch Health Americas, Inc.

Terminated

P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis (AMAGINE-2)

Moderate to Severe Plaque Psoriasis

United States, Austria, France, Poland, Australia, Czechia, Canada, Hungary, Portugal, Spain, Netherlands
Bausch Health Americas, Inc.

Terminated

Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects (AMAGINE-3)

Plaque Psoriasis

United States, Belgium, Italy, Hungary, Poland, Australia, France, Greece, Russian Federation, Latvia, Canada
Amgen
AstraZeneca; Kyowa Kirin Co., Ltd.

Terminated

Study of Efficacy and Safety of Brodalumab Compared With Placebo in Adults With Inadequately Controlled Asthma With High Bronchodilator Reversibility

Asthma

United States, Canada, France, Germany, Italy, Taiwan, Hong Kong, Australia, Greece, Russian Federation, Poland, Ireland, Puerto Rico, Korea, Republic of, New Zealand
Bausch Health Americas, Inc.

Terminated

Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis (AMVISION-1)

Psoriatic Arthritis

United States, Italy, Spain, Hungary, Belgium, Mexico, Poland, Switzerland, United Kingdom, Russian Federation, Canada, Greece, France, Bulgaria, Slovakia, Estonia, Czech Republic
Kyowa Kirin Co., Ltd.

Completed

A Phase 4 Clinical Study of Brodalumab

Psoriasis Vulgaris | Psoriatic Arthritis | Pustular; Psoriasis, Palmaris Et Plantaris | Psoriatic Erythroderma

Japan
First OC Dermatology

Unknown

Brodalumab in Palmoplantar Psoriasis

Palmoplantar Psoriasis
Neil Korman

Recruiting

Mediterranean Diet vs no Dietary Intervention for Improving Signs and Symptoms of Psoriasis in Patients Treated With Anti-IL-17 or Anti-IL-23 Inhibitors

Psoriasis

United States
Rockefeller University
Valeant Pharmaceuticals

Completed

Biomarkers In Hidradenitis Suppurativa Participants Receiving Brodalumab

Hidradenitis Suppurativa

United States
University Hospital, Ghent
KU Leuven; University Ghent

Recruiting

Therapeutic Drug Monitoring of Brodalumab in Psoriasis Patients (BIOLOPTIM-BRO) (BIOLOPTIM-BRO)

Psoriasis Vulgaris

Belgium
Bausch Health Americas, Inc.

Completed

A Bioequivalence Study Comparing a Single 1.5mL Dose of Brodalumab vs. Two Doses (1.0mL + 0.5mL) of Brodalumab

Psoriasis

United States
Rockefeller University

Completed

Molecular Characteristics of Brodalumab in Hidradenitis Suppurativa

Hidradenitis Suppurativa | Acne Inversa

United States
Rockefeller University

Withdrawn

An Alternative Dose Interval Study in Participants With Hidradenitis Suppurativa Receiving Brodalumab

Hidradenitis Suppurativa

United States
LEO Pharma

Recruiting

Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight (ADJUST)

Psoriasis Vulgaris

Belgium, Italy, Spain, Germany, Czechia, Greece, United Kingdom, France, Hungary, Poland, Netherlands
Clinuvel Europe Limited

Recruiting

A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum (XP)

Xeroderma Pigmentosum

Germany
Bausch Health Americas, Inc.

Terminated

Study to Assess the Long-term Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis

Psoriasis

United States, Australia, France, Canada, Denmark
Bausch Health Americas, Inc.

Completed

A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen

Psoriasis

Canada
Amgen

Completed

A Study to Evaluate the Dosing of AMG 827 for Subjects With Inadequately Controlled Asthma

Asthma

United States, Korea, Republic of, Russian Federation, Poland, Finland, Austria, Belgium, Canada, Netherlands, Hungary
Amgen

Withdrawn

Safety, Tolerability, and Pharmacokinetics of AMG 827 in Adolescents With Asthma

Asthma
Aarhus University Hospital
LEO Pharma

Unknown

Effect of Brodalumab Compared to Placebo on Vascular Inflammation in Moderate-to-severe Psoriasis

Psoriasis

Denmark
Bausch Health Americas, Inc.

Recruiting

Canadian Real World Evidence Study of Brodalumab in Plaque Psoriasis to Understand the Impact on Quality of Life and Work Productivity (CARE)

Psoriasis

Canada
Florida Academic Dermatology Centers
Ortho Dermatologics

Unknown

Treatment of Moderate Hidradenitis Suppurativa

Hidradenitis Suppurativa

United States
Amgen

Terminated

Long-term Safety Study of Brodalumab in Adults With Crohn's Disease

Crohn's Disease

United States, France, Belgium, Australia, Netherlands, Spain, Canada, Poland
Amgen

Completed

Study to Evaluate the Safety, PK, PD and Efficacy of AMG 827 in Adults With Rheumatoid Arthritis

Rheumatoid Arthritis
Amgen

Terminated

Brodalumab (AMG 827) in Adults With Moderate to Severe Crohn's Disease

Crohn's Disease

United States, Australia, France, Spain, Canada, Belgium, Netherlands, Poland
Bausch Health Americas, Inc.

Enrolling by invitation

LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis

Psoriasis

United States
Bausch Health Americas, Inc.

Recruiting

An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects

Psoriasis

United States
Bausch Health Americas, Inc.

Completed

Brodalumab Drug-Drug Interaction (DDI) and Intensive Pharmacodynamic (PK) Study in Psoriasis Subjects

Psoriasis

United States, Australia, New Zealand
LEO Pharma

Terminated

Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis (EMBRACE 1)

Psoriasis

Belgium, Germany, Italy, Poland, Spain, France, Greece, Hungary
Association pour la Recherche Clinique et Immunologique

Unknown

Role of Brodalumab in the Modulation of Gut Microbiome in Psoriatic Patients (BOMOGUMIP)

Psoriasis
Amgen

Completed

Brodalumab (AMG 827) in Rheumatoid Arthritis (RA) Participants With Inadequate Response to Methotrexate

Rheumatoid Arthritis
LEO Pharma

Terminated

Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab (COBRA)

Psoriasis | Plaque Psoriasis | Psoriasis Vulgaris

Belgium, Germany, Italy, Spain, Denmark, Austria, France, Greece, Switzerland, United Kingdom, Netherlands, Sweden
Amgen

Terminated

Safety and Efficacy of AMG 827 in Subjects With RA

Rheumatoid Arthritis

United States, Poland, Canada, Bulgaria, Latvia, Czechia, Mexico, United Kingdom
University of Iowa

Enrolling by invitation

Use of Two Dissolvable Therapeutics Under Removable Partial Dentures

Edentulous Jaw | Edentulous Mouth

United States
Radboud University Medical Center
University Hospital, Ghent; ZonMw: The Netherlands Organisation for Health... and other collaborators

Active, not recruiting

Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis (BeNeBio)

Psoriasis | Psoriasis Vulgaris

Netherlands, Belgium

Search clinical trials for: KHK4827 (brodalumab)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Poland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations